Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
Epistemonikos ID: f480fe12d47b120b22e6d74014e2b203275f5534
First added on: May 13, 2024